Psilocybin program

Canadian licensed psychedelics pharmaceutical manufacturer Optimi Health Corp. (OTCQX:OPTHF) has signed an international agreement to supply natural psilocybin to New Zealand-based Mātai Medical Research Institute, on behalf of the Tū Wairua Project.  The agreement marks Optimi’s first...

Certain fungi species that spontaneously produce psilocybin, a powerful substance that activates the serotonin 5-HT2A receptor in the brain and produces psychedelic effects like heightened perception, imagery, complex hallucinations and time distortions, are often called psychedelic or magic...

Melbourne will soon open Clarion Clinics’ first exclusively dedicated facility to provide psychedelic-assisted therapies legalized in Australia.  The subsidiary to biotech Incannex Healthcare (NASDAQ: IXHL) received the required Human Research Ethics Committee (HREC) endorsement for...

John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy The world seemed to come to a momentary halt on December 8, 1980, when news that John Lennon was shot and killed as he approached his apartment building in New York City came out. Lennon...

A COMPASS Pathways (NASDAQ: CMPS)-backed clinical trial assessing psilocybin-assisted psychotherapy for bipolar II disorder has provided preliminary data on the treatment’s safety and efficacy, reported Marijuana Moment’s Ben Adlin. Published by the Journal of the American...

Defense Dept. Funds Ketamine Study For PTSD Treatment  A DOD Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans. The intranasal racemic ketamine was developed by biotech company Seelos...

Australian Coalition Calls For Psychedelic Rules Review Following roughly five months since the country’s Therapeutic Goods Administration (TGA) officially enabled the prescription of MDMA and psilocybin-assisted therapies for certain mental health conditions, a new coalition of healthcare...

The duo comprised of clinical-stage natural psilocybin biotech Psyence Group Inc. and special purpose acquisition company Newcourt Acquisition Corp (NASDAQ: NCAC) announced that the SEC made effective a Form F-4 registration statement for a new business on November 13.  Psyence Group...

The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS) for Treatment-Resistant Depression and Awakn Life Sciences (OTCMKTS: AWKNF) for Severe Alcohol Use Disorder (SAUD). Details On Trials Compass...

The first of several of PharmAla Biotech’s (OTC: PMBHF) shipments of psychedelic molecules -both API and finished drug product capsules- to its Australian JV Cortexa for use under the Authorized Prescriber Scheme (APS) is all set. The Canadian MDXX class molecules company, together with...

COMPASS Pathways plc (NASDAQ: CMPS), the London-headquartered psychedelics biotech company reported financial results for the third quarter 2023 ended September 30, showing:  Cash and cash equivalents of $248.0 million as of Sept. 30, 67% more than that held on last quarter’s...

Psychedelics company Cybin Inc. (NYSE: CYBN) shared its Phase 2 study interim results for its psilocybin analog CYB003 on Major Depressive Disorder (MDD) paired with the company’s EMBARK psychotherapy.  The new data met the trial’s primary efficacy endpoint: A rapid, robust...

What can businesses and clients expect of the incoming psychedelic-assisted therapies (PAT) scenario? What are state regulations looking like from a for-profit perspective, and what does it take to provide safe, effective and regulations-compliant treatments? Around these and other concerns,...

Editor's note: This story has been updated to clarify that Kelsi Sheren's treatment does not represent the first legal access to medical psilocybin in Canada.  Health Canada’s Special Access Program (SAP) has authorized a physician to provide Apex Labs’ psilocybin macrodose...

Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD.)  All participants in the sixth and final cohort have reportedly received at least...